BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29662658)

  • 1. Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment.
    Ogino Y; Sato A; Uchiumi F; Tanuma SI
    Oncotarget; 2018 Mar; 9(23):16451-16461. PubMed ID: 29662658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
    Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
    Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
    Ogino Y; Sato A; Uchiumi F; Tanuma SI
    Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure-based comparison of two NAMPT inhibitors.
    Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
    Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
    Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
    Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth.
    Pant K; Richard S; Peixoto E; Yin J; Seelig DM; Carotenuto P; Salati M; Franco B; Roberts LR; Gradilone SA
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
    Okumura S; Sasaki T; Minami Y; Ohsaki Y
    J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
    Nagaya M; Hara H; Kamiya T; Adachi T
    Arch Biochem Biophys; 2019 Nov; 676():108155. PubMed ID: 31628926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor.
    Kozako T; Aikawa A; Ohsugi T; Uchida YI; Kato N; Sato K; Ishitsuka K; Yoshimitsu M; Honda SI
    Eur J Pharmacol; 2019 Dec; 865():172738. PubMed ID: 31614144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
    Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
    Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
    Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
    Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial rewiring drives metabolic adaptation to NAD(H) shortage in triple negative breast cancer cells.
    Carreira ASA; Ravera S; Zucal C; Thongon N; Caffa I; Astigiano C; Bertola N; Buongiorno A; Roccuzzo M; Bisio A; Pardini B; Nencioni A; Bruzzone S; Provenzani A
    Neoplasia; 2023 Jul; 41():100903. PubMed ID: 37148658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.
    Song TY; Yeh SL; Hu ML; Chen MY; Yang NC
    Biogerontology; 2015 Dec; 16(6):789-800. PubMed ID: 26330291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA.
    Thongon N; Zucal C; D'Agostino VG; Tebaldi T; Ravera S; Zamporlini F; Piacente F; Moschoi R; Raffaelli N; Quattrone A; Nencioni A; Peyron JF; Provenzani A
    Cancer Metab; 2018; 6():1. PubMed ID: 29541451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment.
    Zeng M; Wei TF; Chen C; Shen C; Gao TY; Xie X; Wu M; Lu YB; Zhang WP
    J Cereb Blood Flow Metab; 2021 Oct; 41(10):2510-2523. PubMed ID: 33818184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
    Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
    Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
    Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
    Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents.
    Conforti I; Benzi A; Caffa I; Bruzzone S; Nencioni A; Marra A
    Med Chem; 2024 Feb; ():. PubMed ID: 38333979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.
    Espindola-Netto JM; Chini CCS; Tarragó M; Wang E; Dutta S; Pal K; Mukhopadhyay D; Sola-Penna M; Chini EN
    Oncotarget; 2017 Oct; 8(49):85054-85067. PubMed ID: 29156703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors.
    Tanuma SI; Katsuragi K; Oyama T; Yoshimori A; Shibasaki Y; Asawa Y; Yamazaki H; Makino K; Okazawa M; Ogino Y; Sakamoto Y; Nomura M; Sato A; Abe H; Nakamura H; Takahashi H; Tanuma N; Uchiumi F
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32785052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.